Recarbrio patents expiration

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Recarbrio is owned by Msd Merck Co.

Recarbrio contains Cilastatin Sodium; Imipenem; Relebactam.

Recarbrio has a total of 1 drug patent out of which 0 drug patents have expired.

Recarbrio was authorised for market use on 16 July, 2019.

Recarbrio is available in powder;intravenous dosage forms.

Recarbrio can be used as treatment of complicated intra-abdominal infections (ciai); treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); treatment of complicated urinary tract infections, including pyelonephritis (cuti).

Drug patent challenges can be filed against Recarbrio from 2028-07-16.

The generics of Recarbrio are possible to be released after 19 November, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 2028-07-16

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...


More Information on Dosage

RECARBRIO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic